Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)

Abstract Pomalidomide has been shown to improve survival in patients with relapsed/refractory myeloma (RRMM). However, the optimal pomalidomide-based combinations in RRMM are not known. This study compared pomalidomide, cyclophosphamide, dexamethasone (PCD) with pomalidomide and dexamethasone (PD) i...

Descrición completa

Detalles Bibliográficos

Principais autores:	Jin Seok Kim, Yang Song, Wei-Ying Jen, C. S. Chim, Je-Jung Lee, Sung-Soo Yoon, Soo Chin Ng, Gin Gin Gan, Hiroshi Handa, Jae Hoon Lee, Kihyun Kim, Shigeki Ito, Jeffrey Shang-Yi Huang, Chang Ki Min, Melissa Ooi Gaik Ming, Sanjay de Mel, Cinnie Soekojo, Xinhua Li, Neha Awasthi, Yogesh Pokharkar, Brian GM Durie, Wee-Joo Chng
Formato:	Artigo
Idioma:	Inglês
Publicado:	Nature Publishing Group 2025-10-01
Series:	Blood Cancer Journal
Acceso en liña:	https://doi.org/10.1038/s41408-025-01356-z
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!